Talzenna (Talazoparib)
- Medicine Name: Talzenna
- Generic Name: Talazoparib
- Dosage Form & Strength: Capsules: 0.25 mg, 1 mg
- Manufactured By: Pfizer Inc.
Talzenna is a poly (ADP-ribose) polymerase (PARP) inhibitor used for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.
Recommended Dosage: The recommended dose of Talzenna Capsule is 1 mg taken orally once daily, with or without food. When the dose reduction is required, 0.25 mg capsules can also be used. Patients should be treated until the disease is progressive or unacceptable toxicity occurs.
The hard capsules of Talzenna should be swallowed whole and must not be opened or dissolved. If a patient misses or vomits a dose, an additional dose of Talzenna should not be taken. Take the very next prescribed dose at the usual time.
- Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) may be reported in those who received Talzenna 0.25mg capsules. Do not start treatment until patients have adequately recovered from hematological toxicity due to previous chemotherapy.
- CBC needs to be monitored for cytopenia at baseline and then monthly basis. For prolonged hematological toxicities, interrupt treatment and assess blood counts weekly until recovery. In case the levels have not recovered after four weeks, refer the patient to a hematologist for further evaluations, including bone marrow analysis and blood sample for cytogenetics. In case MDS/AML is suspected, discontinue treatment.
- Myelosuppression consisting of leukopenia/neutropenia, anemia, or thrombocytopenia, may occur in those treated with Talzenna 0.25mg or with any other dosage strength. Monitor complete blood count (CBC) for cytopenia at baseline and monthly thereafter.
- Depending on its mechanism of action and data, Talazoparib treatment can cause fetal harm if used by pregnant women. Those with reproductive age should use apt contraception during therapy and for at least seven months following the final dose of Talazoparib.
- Due to the risk for serious side effects in a breastfed child from Talazoparib 1mg Capsule, lactating women should not breastfeed throughout the treatment and for at least 40 days after the last dose. A pregnancy test is required for females of reproductive age prior to initiating Talazoparib treatment.
What documents are required to import TALZENNA® to India?
TALZENNA® (Talazoparib) capsules can be imported by patients or government hospitals on the name of the patients only.
The following documentation are needed to import the medicinal product:
- Valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients Proof of Identity (issued by government of India)
How does order be confirmed?
The order will be confirmed only after the receipt of:
- Valid prescription of Doctor
- Import permit if applicable
Is TALZENNA® available in India?
TALZENNA® (Talazoparib Capsule) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
- On availability of Talzenna 0.25mg in India (Delhi, Mumbai, Kolkata, Hyderabad, Ahmedabad, Pune, Bangalore and Chennai etc.)
- Medicine Price.
- Finding the most reliable and genuine source from the USA, Canada, Europe, and Australia.
- Ensuring 100% transparency.
TALZENNA® can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of TALZENNA® (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).
Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Talzenna Capsules price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network is able to source the TALZENNA® (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma Network offers its customers worldwide access to the best available treatment.
Indian Pharma Network (IPN) is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Talzenna®?
Talazoparib is Generic Name for the trade name drug Talzenna®.
What is the Manufacturer Name of Talzenna®?
Talzenna® is manufactured by Pfizer Inc.
Is Talzenna® approved by the FDA?
Yes, Talzenna® is approved by the FDA. Date of first/initial approval: October 16, 2018.
What is the dosage and form of Talzenna® supplied?
Talzenna® is supplied as Capsules: 0.25 mg, 1 mg for oral administration.
What are the most common side effects with Talzenna®?
The most common side effects with Talzenna® include: nausea, fatigue, anemia, neutropenia, thrombocytopenia, headache, vomiting, alopecia, decreased appetite, and diarrhea.
How much does Talzenna® cost in India?
Talzenna cost in India is very reasonable. To procure this Breast Cancer medication authentically, you can dial our TOLL-FREE: 1800-889-1064, or Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Talzenna®?
Store the capsules at temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).
Is it safe to buy Talzenna® online from India?
Yes, You can Buy Talzenna 0.25 mg and 1 mg online from India authentically from https://www.indianpharmanetwork.in/ if Talzenna is not available or has not been approved in your home country.
What are the Highlights of prescribing information for Talzenna®?
Click Here to download full Talzenna prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.